The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | RATIONALE-305: impact of tislelizumab + chemotherapy on patient-reported outcomes
Marcia Cruz-Correa, MD, PhD, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico, comments on the results of a global trial that investigated the efficacy of tislelizumab, an anti-PD-1 inhibitor, as a first-line therapy in patients with gastric cancer. Dr Cruz-Correa highlights that patients who received tislelizumab in addition to chemotherapy had a significant improvement in overall survival and patient-reported outcomes, including reduced abdominal pain and improved nutrition, compared to those receiving standard of care. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
